This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: Approval of NVS & ABBV Cancer Drugs, MRK's HIV Drug in Focus
by Zacks Equity Research
Novartis (NVS) & AbbVie (ABBV) get cancer approvals. Merck (MRK) gets FDA nod for two new HIV medicines.
4 Large Cap Pharma Stocks in Focus on Robust Cancer Pipeline
by Kinjel Shah
We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)
by Zacks Equity Research
Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.
Affimed (AFMD) Surges On Collaboration Contract With Roche
by Zacks Equity Research
Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.
Pfizer Stock Up This Year So Far: What's Going in its Favor?
by Zacks Equity Research
Pfizer's (PFE) stock is on an upward trajectory this year. Let us have a look at the reasons for the same.
AbbVie's Imbruvica Combo Gets FDA Nod for Rare Lymphoma
by Zacks Equity Research
AbbVie's (ABBV) cancer drug Imbruvica gets FDA approval for use in combination with Roche's Rituxan for Waldenstrom's macroglobulinemia (WM), a rare form of Non-Hodgkin's lymphoma.
Roche (RHHBY) Gets FDA Approval for Cobas EFGR Mutation Test
by Zacks Equity Research
Roche's (RHHBY) cobas EGFR Mutation Test v2 gets FDA nod as a companion diagnostic test with IRESSA.
Novartis Breast Cancer Drug Meets Primary Goal in Phase III
by Zacks Equity Research
Novartis' (NVS) late-stage candidate, BYL719, meets primary endpoint in SOLAR trial on advanced breast cancer patients.
Large-Cap Pharma Rebounds: 2 Stocks to Boost Your Portfolio
by Kinjel Shah
The large-cap pharma industry is on track to recovery. Here are two stocks from the space that investors may consider betting on.
Horizon Pharma (HZNP) Boasts Robust Pipeline Amid Competition
by Zacks Equity Research
Horizon Pharma (HZNP) remains focused on advancing its pipeline candidates and is also making efforts to expand the label of its already approved drugs.
Bristol-Myers' Opdivo Gets FDA Nod for Small Cell Lung Cancer
by Zacks Equity Research
Bristol-Myers' (BMY) blockbuster immuno-oncology drug Opdivo gets the FDA approval for small cell lung cancer indication, which shall further expand the addressable patient population of the drug.
Roche's Lung Cancer Drug Alecensa Gets Approval in China
by Zacks Equity Research
The China National Drug Administration approves Roche's (RHHBY) cancer drug Alecensa as a monotherapy for first-line treatment of advanced non-small cell lung cancer.
Amgen Stock Up This Year So Far: Will the Rally Continue?
by Zacks Equity Research
After a relatively strong performance so far this year, let's see how things are poised for Amgen (AMGN) in the second half of the year.
Pain Therapeutics' Shares Rally on Alzheimer's Study Grant
by Zacks Equity Research
Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.
Agenus (AGEN) Delivering Well on Its Pipeline Candidates
by Zacks Equity Research
We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.
What's in Store for Amgen (AMGN) in Second Half of 2018?
by Zacks Equity Research
After a relatively strong first half, let's see how things are poised for Amgen (AMGN) in the second half of the year.
Allergan's (AGN) Stock Up 4.2% Since Q2 Earnings: Here's Why
by Zacks Equity Research
Allergan (AGN) is having a relatively better 2018 with the stock on an upward trajectory since announcement of earnings in July. Let us have a look at the reasons for the same.
Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status
by Zacks Equity Research
Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
by Zacks Equity Research
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
Mylan (MYL) Q2 Earnings and Revenues Miss, Guidance Cut
by Zacks Equity Research
Mylan is expected to loose ground after its second-quarter results miss estimates. The cut in guidance is disappointing as well.
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings?
by Zacks Equity Research
During the second-quarter earnings call, Horizon Pharma (HZNP) will focus on the performance of business units along with that of Actimmune and Krystexxa and update on teprotumumab's development.
Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?
by Zacks Equity Research
Prothena's (PRTA) Q2 results are likely to reflect pipeline updates along with progress with its restructuring plan.
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Clovis (CLVS) misses bottom-line estimates in the second quarter but beats on the top line. Rubraca sales increase.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss and beats revenue estimates in the second quarter of 2018.